1. Cell Cycle/DNA Damage
  2. CDK


CDKs (Cyclin-dependent kinases) are a family of protein kinases first discovered for their role in regulating the cell cycle. Types: Cdk1, Cdk2, Cdk3, Cdk4, Cdk5, Cdk6, Cdk7, Cdk8, Cdk9, Cdk11. They are also involved in regulating transcription, mRNA processing, and the differentiation of nerve cells. They are present in all knowneukaryotes, and their regulatory function in the cell cycle has been evolutionarily conserved. CDKs are relatively small proteins, with molecular weights ranging from 34 to 40 kDa, and contain little more than the kinase domain. By definition, a CDK binds a regulatory protein called a cyclin. Without cyclin, CDK has little kinase activity; only the cyclin-CDK complex is an active kinase. CDKs phosphorylate their substrates on serines and threonines, so they are serine-threonine kinases. CDK levels remains relatively constant throughout the cell cycle and most regulation is post-translational. Most knowledge of CDK structure and function is based on CDKs of S. pombe (Cdc2), S. cerevisiae (CDC28), and vertebrates (CDC2 and CDK2). The four major mechanisms of CDK regulation are cyclin binding, CAK phosphorylation, regulatory inhibitory phosphorylation, and binding of CDK inhibitory subunits (CKIs).

CDK Related Products (69):

Cat. No. Product Name Effect Purity
  • HY-50767
    Palbociclib Inhibitor
    Palbociclib is a highly specific inhibitor of Cdk4 (IC50=11 nM) and Cdk6 (IC50=16 nM), having no activity against a panel of 36 additional protein kinases.
  • HY-10492
    Dinaciclib Inhibitor
    Dinaciclib is a potent and selective inhibitor of CDKs, with IC90s of of 1, 1, 3, and 4 nM for CDK2, CDK5, CDK1, and CDK9 activity, respectively.
  • HY-30237
    Roscovitine Inhibitor
    Roscovitine is a potent and selective CDK inhibitor with IC50 of 0.2 μM, 0.65 μM, and 0.7 μM for CDK5, Cdc2, and CDK2, respectively.
  • HY-10005
    Flavopiridol Inhibitor
    Flavopiridol is a broad inhibitor of CDK, competing with ATP to inhibit CDKs including CDK1, CDK2, CDK4 and CDK6 with IC50 of around 40 nM.
  • HY-13266
    BS-181 Inhibitor
    BS-181 is a highly selective CDK7 inhibitor with IC50 of 21 nM, and > 40-fold selective for CDK7 than CDK1, 2, 4, 5, 6, or 9.
  • HY-12871
    BAY-1143572 Inhibitor
    BAY 1143572 is a highly selective, potent and orally available inhibitor of PTEFb/CDK9; inhibits the proliferation of AML cell lines with a median IC50 of 385 nM.
  • HY-10012
    AZD-5438 Inhibitor
    AZD-5438 is a potent inhibitor of CDK1/2/9 with IC50 of 16 nM/6 nM/20 nM in cell-free assays. It also inhibits GSK3β, but is less potent to CDK5/6.
  • HY-10008
    SNS-032 Inhibitor
    SNS-032 is a selective inhibitor of cyclin-dependent kinase (CDK), inhibiting CDK2/7/9 with IC50s of 48 nM/62 nM/4 nM.
  • HY-10580
    BIO Inhibitor
    BIO is a potent and selective inhibitor of GSK-3 and CDK1-cyclinB complex with IC50s of 5 nM/320 nM/83 nM for GSK-3αβ/CDK1/CDK5, respectively.
  • HY-15338
    TG003 Inhibitor
    TG003 is a potent inhibitor of Clk1/Sty; inhibits Clk1 and Clk4 with IC50 values of 20 and 15 nM, respectively.
  • HY-15339
    CVT-313 Inhibitor
    CVT-313 is a potent, selective, reversible, and ATP-competitive inhibitor of CDK2 wirh IC50 of 0.5 μM.
  • HY-13231
    CDK9-IN-1 Inhibitor
    CDK9-IN-1 is a novel, selective CDK9 inhibitor for the treatment of HIV infection.
  • HY-15166
    SB1317 Inhibitor
    SB1317 is a potent inhibitor of CDK2, JAK2, and FLT3 for the treatment of cancer, with IC50 of 13, 73, and 56 nM for CDK2, JAK2 and FLT3, respectively.
  • HY-11001
    PHA-793887 Inhibitor
    PHA-793887 is a novel pan-cdk inhibitor, including cdk1, cdk2, cdk4, cdk5, cdk7, and cdk9 with IC50 in the 5 to 140 nM range.
  • HY-50943
    AT7519 Hydrochloride Inhibitor
    AT7519 hydrochloride is a multi-CDK inhibitor for CDK1, 2, 4, 6 and 9 with IC50 of 10-210 nM; is less potent to CDK3 and little active to CDK7.
  • HY-10006
    Flavopiridol Hydrochloride Inhibitor
    Flavopiridol hydrochloride competes with ATP to inhibit CDKs including CDK1, CDK2, CDK4 and CDK6 with IC50 of ~ 40 nM.
  • HY-10424
    PHA-848125 Inhibitor
    PHA-848125(Milciclib) is a potent, ATP-competitive CDK inhibitor for CDK2 with IC50 of 45 nM; >3-fold more selective for CDK2 than CDK1, 2, 4, 5, and 7.
  • HY-15275
    BMS-265246 Inhibitor
    BMS-265246 is a potent and selective CDK1/2 inhibitor for CDK1/cyclin B and CDK2/cyclin E with IC50 of 6 nM and 9 nM, respectively.
  • HY-10329
    JNJ-7706621 Inhibitor
    JNJ-7706621 is pan-CDK inhibitor with the highest potency on CDK1/2 with IC50 of 9 nM/4 nM and showing >6-fold selectivity for CDK1/2 than CDK3/4/6; also potently inhibits Aurora A/B and has no activity on Plk1 and Wee1.
  • HY-15260A
    XL413 hydrochloride Inhibitor
    XL413 is a potent and selective Cdc7 inhibitor with an IC50 of 3.7 nM, >60-fold selectivity against CK2, >10-fold selectivity against PIM, and >300-fold selectivity against a panel of over 100 protein kinases.